Aptevo Secures $60M Equity Line, Reports Strong AML Data & Q1 Results

summarizeSummary

Aptevo Therapeutics secured a new $60 million equity line of credit, providing critical financial flexibility and runway, alongside reporting strong interim clinical data for its lead drug candidate, mipletamig, in acute myeloid leukemia.

check_boxKey Events

• Secured $60 Million Equity Line of Credit

  Aptevo Therapeutics entered into a new $60 million Standby Equity Purchase Agreement (SEPA), significantly enhancing its financial flexibility and extending its access to capital through key catalysts into 2029. This financing is crucial for the company, which previously disclosed going concern doubts.

• Strong Mipletamig Clinical Data in AML

  The company reported compelling interim data for its lead immune-oncology therapeutic, mipletamig, in combination with venetoclax + azacitidine for frontline Acute Myeloid Leukemia (AML). Data showed an 87% clinical benefit rate and 81% remission (CR or CRi), outperforming a Phase 3 comparator trial, with no observed cytokine release syndrome (CRS).

• Q1 2026 Financial Update

  Aptevo reported cash and cash equivalents totaling $14.5 million as of March 31, 2026. The company raised $0.9 million, net, under its existing SEPAs during the first quarter.

• Completed Leadership Transition

  Jeff Lamothe has been appointed President and Chief Executive Officer, with Marvin White transitioning to Executive Chair, completing a planned executive leadership transition.

auto_awesomeAnalysis

This filing is critical for Aptevo Therapeutics, a company that recently disclosed substantial doubt about its ability to continue as a going concern. The new $60 million Standby Equity Purchase Agreement (SEPA) provides a vital financial lifeline, extending the company's capital access through key catalysts into 2029. While highly dilutive given the company's current market capitalization, this financing is essential for the company's survival and ability to advance its promising drug pipeline. Concurrently, the company reported compelling interim clinical data for mipletamig in frontline AML, showing superior remission rates and a favorable safety profile, which significantly de-risks the clinical program and supports future value creation if the company can remain operational.